Just one of the many VHIO studies showcased during this week’s prestigious 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO), 01 – 05 June, Chicago, included a new definition of hyperprogession disease (HPD) with immune checkpoint inhibitors that has recently been described as progression disease (PD) by RECIST with a ≥ two-fold increase in tumor growth rate experimental versus reference. Presented as a poster by first author Ignacio Matos, Phase I Investigator of VHIO’s Early Clinical Development Group and Associate Investigator of our Research Unit for Molecular Therapy of Cancer (UITM) – “la Caixa”, the study sought to resolve the challenges of implementing this assessment in clinical practice.
Premier oncology channel ecancer caught up with Elena Garralda, Principal Investigator of the same group and Executive Director of VHIO’s leading phase I Unit, during the meeting to discuss our portfolio of early phase immunotherapy trials as well as the findings that have subsequently established a definition of HPD that is both intuitive and easily applicable in the clinic.
To discover what Elena had to say, please click on the image below:
